8 [89] M. Krampera, S. Glennie, J. Dyson et al., “Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-speciﬁc T cells to their cognate peptide,” Blood, vol. 101, no. 9, pp. 3722–3729, 2003. [90] F. Dazzi and F. M. Marelli-Berg, “Mesenchymal stem cells for graft-versus-host disease: close encounters with T cells,” European Journal of Immunology, vol. 38, no. 6, pp. 1479–1482, 2008. [91] K. Le Blanc, I. Rasmusson, C. Go˝therstro˝m et al., “Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin- activated lymphocytes,” Scandinavian Journal of Immunology, vol. 60, no. 3, pp. 307–315, 2004. [92] A. Corcione, F. Benvenuto, E. Ferretti et al., “Human mesenchymal stem cells modulate B-cell functions,” Blood, vol. 107, no. 1, pp. 367–372, 2006. [93] K. English, F. P. Barry, and B. P. Mahon, “Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation,” Immunology Letters, vol. 115, no. 1, pp. 50–58, 2008. [94] H. Y. Lai, M. J. Yang, K. C. Wen, K. C. Chao, C. C. Shih, and O. K. Lee, “Mesenchymal stem cells negatively regulate dendritic lineage commitment of umbilical-cord-blood-derived hema- topoietic stem cells: an unappreciated mechanism as im- munomodulators,” Tissue Engineering, vol. 16, no. 9, pp. 2987–2997, 2010. [95] S. Pulavendran, J. Vignesh, and C. Rose, “Diﬀerential anti- inﬂammatory and anti-ﬁbrotic activity of transplanted mes- enchymal vs. hematopoietic stem cells in carbon tetrachlo- ride-induced liver injury in mice,” International Immuno- pharmacology, vol. 10, no. 4, pp. 513–519, 2010. [96] D. Polchert, J. Sobinsky, G. Douglas et al., “IFN-γ activation of mesenchymal stem cells for treatment and prevention of graft versus host disease,” European Journal of Immunology, vol. 38, no. 6, pp. 1745–1755, 2008. [97] G. M. Spaggiari, A. Capobianco, S. Becchetti, M. C. Mingari, and L. Moretta, “Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation,” Blood, vol. 107, no. 4, pp. 1484–1490, 2006. [98] S. Ghannam, C. Bouﬃ, F. Djouad, C. Jorgensen, and D. Noe¨l, “Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications,” Stem Cell Research and Therapy, vol. 1, no. 1, pp. 2–8, 2010. [99] A. Chapel, J. M. Bertho, M. Bensidhoum et al., “Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome,” Journal of Gene Medicine, vol. 5, no. 12, pp. 1028–1038, 2003. Bone Marrow Research